Clinical trials: Heart Failure, Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
This multicentre, prospective, single-arm cohort study will evaluate the real-world effectiveness and safety of Savagen, an NPRA-approved generic sacubitril/valsartan, in Malaysian adults aged 18 to 70 years with heart failure…
- Trial name
- NCT07907640
- Testing
- Savagen (sacubitril/valsartan)
- Where
- 2 sites in Malaysia
- Volunteers
- 80 people
- Sponsor
- Sunway University
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 686 sites in United States, Argentina and 33 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Heart Failure, Worsening Heart Failure
Metabolic Changes in Heart Failure Patients Treated With Vericiguat
Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention.
- Conditions
- Heart Failure, Worsening Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- VERI-MET (NCT07901270)
- Testing
- Vericiguat
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Salerno
HFrEF - Heart Failure With Reduced Ejection Fraction
Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- Vsling III (NCT06002386)
- Testing
- Vsling
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Cardiac Success
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
- Trial name
- NCT06632483
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- India
- Volunteers
- 604 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction
Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- NCT06851949
- Testing
- Vsling
- Where
- 5 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Cardiac Success
Chronic Heart Failure With Reduced Ejection Fraction
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
This study will evaluate the efficacy and safety and the best effective dose of QiShen YiQi Dripping Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis…
- Trial name
- NCT04983043
- Testing
- Low dose QiShen YiQi Dripping Pills 3 bags, High dose QiShen YiQi Dripping Pills 3 bags
- Where
- 23 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure With Reduced Ejection Fraction
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.
- Trial name
- RECOVER-HF (NCT06552637)
- Testing
- Synchronized Diaphragmatic Stimulation
- Where
- 5 sites in United States, Georgia
- Volunteers
- 270 people
- Sponsor
- VisCardia Inc.
Heart Failure With Reduced Ejection Fraction
HFrEF Polypill in Sri Lanka RCT
The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure…
- Trial name
- NCT07569640
- Testing
- Usual Care, HFrEF Polypill
- Where
- 12 sites in Sri Lanka
- Volunteers
- 1,672 people
- Sponsor
- Washington University School of Medicine
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease
Assessment of Biomarkers in Patients with Decompensated Heart Failure and Underlying Coronary Artery Disease
- Trial name
- NCT03551756
- Testing
- Biomarker Assessment
- Where
- 3 sites in United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- CirQuest Labs, LLC
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function.
- Conditions
- Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF), Rate Control
- Trial name
- NCT07272902
- Testing
- Catheter Ablation for Atrial Fibrillation, Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)
- Where
- 4 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Nova Scotia Health Authority
Heart Failure, Acute Heart Failure
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure.
- Conditions
- Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PopS-HF (NCT07295522)
- Testing
- Guideline-Directed Medical Therapy (GDMT)
- Where
- 12 sites in Italy
- Volunteers
- 368 people
- Sponsor
- IRCCS Policlinico S. Donato
Heart Failure With Reduced Ejection Fraction (HFrEF)
Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction
The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure…
- Trial name
- OLEA-HF (NCT07644806)
- Testing
- Extra-virgin olive oil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Old Dominion University
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF)
Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
Atrial Fibrillation (AF) and Heart Failure (HF) are colliding global cardiovascular epidemics, individually impairing quality of life and cardiac performance, as well as increasing the risk of hospitalisation and mortality.
- Trial name
- OPTIMal AF-HF (NCT07238452)
- Testing
- Pulmonary Vein Isolation, Pharmacological Rate Control
- Volunteers
- 1,050 people
- Sponsor
- University of British Columbia
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 209 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.